Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2019

Open Access 01-12-2019 | Schizophrenia | Research article

Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study

Authors: Yirgalem Shewakena Wubeshet, Oumer Sada Mohammed, Tigestu Alemu Desse

Published in: BMC Psychiatry | Issue 1/2019

Login to get access

Abstract

Background

First-generation antipsychotics (FGAs) are associated with a range of adverse events which can significantly reduce patients’ quality of life and contribute to non-adherence. The aim of this study was to assess the prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients.

Methods

The study was conducted at Amanuel Mental Specialized Hospital from March to June, 2017. Data from patients were collected using a pretested structured questionnaire. Demographics and side effects of antipsychotics were collected by face to face interview. Clinical characteristics, medications and previous history of adverse drug events were extracted from medical records using data abstraction format. The data were analyzed using statistical software for social sciences (SPSS) version 20. Descriptive statistics and chi-square tests were done. Statistical significance was considered at p < 0.05.

Results

Out of 356 participants, 300 of them had complete data and were included in the study. The mean age of participants was 33.71 ± 10.2 years. The majority, 195(65.0%), of participants were males. Most of the participants, 293(97.7%), developed FGA medication induced side effects. One hundred sixty three (54.3%) participants were treated with Trihexyphenidyl for FGAs induced side effects. Dose reduction of antipsychotics was done for 51(17.0%) participants. Most of the participants’ side effects were not managed according to American Psychiatric Association guideline; 178 (82.4%). The most common types of FGAs induced side effects were cardiovascular side effects 169(56.3%); sedation and CNS side effects 149(49.6%); and extrapyramidal side effects 114(38.0%). There is a significant association between occurrence of side effects of FGAs and duration of illness (P = 0.04).

Conclusions

The prevalence of first generation antipsychotics induced side effects was high. However, management practice of the side effects was minimal.
Literature
1.
The National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people. In: The British Psychological Society and the Royal College of psychiatrists; 2013.
2.
3.
Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications:a systematic review and meta-analysis. Ann Intern Med. 2017;157(20):498–511.
4.
Naber D, Karow A, Lambert M. 3-subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand. 2005;111(427):29–3.CrossRef
5.
Lewis W, Barnes TRE, Jones PB, Peluso MJ. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200:387–92.CrossRef
6.
Miller DD, Caroff SN, Davis SM, Rosenheck RA, Mcevoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193:279–88.CrossRef
7.
Lane A, Bentall RP. Doctoring the mind. In: Why psychiatric treatments fail. London: Allen Lane; 2009. p. 99889.
8.
Joy Y. Managing Side Effects of Anxiolytics. Primary Psychiatry. 2007;14(7)68–76.
9.
Jeffrey A, Kane JM. Prospective study of tardive dyskinesia in the Elderly : rates and risk factors. Am J Psychiatry. 1998;155(November):1521–8.
10.
Ayano G. First generation antipsychotics: pharmacokinetics, pharmacodynamics, therapeutic effects and side effects: a review. RRJCHEM. 2016;5(3):53–63.
11.
Zhao YJ, Lin L, Teng M, Khoo AL, Soh L, Furukawa TA, et al. Long-term antipsychotic treatment in schizophrenia : systematic review and network meta-analysis of randomised controlled trials. BJPsych. 2016;(2):59–66.
12.
Abou-Setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, Armijo-Olivo S, et al. First-generation versus second-generation antipsychotics in adults : comparative effectiveness. National Institute for Health Research; Centre for Reviews and DisseminationDatabase of Abstracts of Reviews of Effects (DARE). 2017:1–4.
13.
Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence : results of a cross- sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(20):1–7.
14.
Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E, Winseck A. The Impact of Medication Side Effects on Adherence among Patients with Schizophrenia: Results of a Cross-Sectional Nationwide Survey. In: Presented at the American Psychiatric Association (APA) 2011 Annual meeting, may 14–18, 2011, Honolulu, Hawai’i 2011. p. 2011.
15.
16.
Holder SD, AL E, Morgan S. Psychotic and Bipolar Disorders_ Antipsychotic Drugs. FP Ess. 2017;April(455):23–9.
17.
Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci. 2006;1(9–14):9–14.
18.
Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008;22(3):238–43.CrossRef
19.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. Naranjo ADR Scale. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRef
20.
Richard B.Practical Management of the Side Effects of psychotropic drugs. Marcel Dekker Marcel Dekker, Inc . 1999. 329 p.
21.
Mentzel TQ, Lieverse R, Bloemen O, van HP VW. High incidence and prevalence of drug-related movement disorders in young patients with Psychotic disorders. J Clin Psychopharmacol. 2017;37(2):231–8.CrossRef
22.
Tanifuji H. Tensho M. concurrent use of medications in schizophrenic outpatients. Psychiatry Clin Neurosci. 2012;66:405–10.CrossRef
23.
Go CL, Rosales RL, Rico J, Caraos RJ, Fernandez HH. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients - Parkinsonism & Related Disorders. Park Relat Disord. 2009;15(9):655–9.CrossRef
24.
Taye H, Awoke T, Ebrahim J. Antipsychotic medication induced movement disorders: the case of Amanuel specialized mental hospital, Addis Ababa, Ethiopia. Am J Psychiatry Neurosci. 2014;2(5):76–82.CrossRef
25.
26.
Wang X, Zhang W, Ph D, Ma N, Guan L, Ph D, et al. Adherence to Antipsychotic medication by community-based patients with schizophrenia in China : a cross-sectional study. Psychiatr Serv. 2014;67(11):431–7.
27.
King D, Knapp M, Patel A, Tansella M, Schene A, Koeter M. The impact of non-adherence to medication in patients with schizophrenia on health. In: Social care and societal costs : analysis of the QUATRO study; 2014.
28.
Psych DIP, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-Induced Mov Disord: Evaluation and Treatment. Psychiatry. 2005;March(215):36–41.
29.
Ferrin M, Gosney H, Marconi A, Rey JM. Using antipsychotic medication for the treatment of schizophrenia in children and adolescents. In: Rey JM, editor. IACAPAP e-textbook of child and adolescent mental health. Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions; 2016.
30.
Shen WW, Su K. The Torsadogenic risk of Antipsychotic drugs. Taiwan J Psychiatry. 2000;14(3):166–81.
31.
Hert M De, Detraux J, Winkel R Van, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Endocrinol 2012;8(February):114–126.
32.
Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325(November):1–5.
33.
Mersey Care. Clinical Guideline / Formulary Document. Side Effects Of Psychotropic Medicines. 2017:1–11.
34.
Naja WJ, Halaby A. Journal of Alcoholism & Drug Anticholinergic use and misuse in Psychiatry : a comprehensive and critical review. J Alcohol Drug Depend. 2017;5(2):5–8.CrossRef
35.
Roth BLS. Recognizing and avoiding common pitfalls in clinical psychopharmacology. Published on Psychiatric Times. 2007.
36.
Hong IS, Bishop JR. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother. 2013;13(4):244–51.
Metadata
Title
Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study
Authors
Yirgalem Shewakena Wubeshet
Oumer Sada Mohammed
Tigestu Alemu Desse
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2019
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1999-x

Other articles of this Issue 1/2019

BMC Psychiatry 1/2019 Go to the issue

Study protocol

The Momentum trial: the efficacy of using a smartphone application to promote patient activation and support shared decision making in people with a diagnosis of schizophrenia in outpatient treatment settings: a randomized controlled single-blind trial

Research article

Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification

Study protocol

Study design of the Routine Outcome Monitoring for Geriatric Psychiatry & Science (ROM-GPS) project; a cohort study of older patients with affective disorders referred for specialised geriatric mental health care

Case report

A case report of the successful administration of clozapine in the face of myocardial infarction, pulmonary embolism and hyperlipidaemia resulting in the termination of long-term seclusion

Research article

Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice

Research article

A group randomized control trial to test the efficacy of the Road to Mental Readiness (R2MR) program among Canadian military recruits